HR Execs on the Move

Inocucor

www.inocucor.com

 
The Phyto-Microbiome Company Biological Optimizers for Soil, Seed and Plant Vigor Inocucor is an agri-tech company that develops powerful natural biological products for agriculture targeting the phyto-microbiome—the seeds, plants, root systems and the soil surrounding them. Inocucor`s first-generation product, Garden Solution®, soon to be re-branded as Synergro, employs live microbes to actively improve the health of the entire phyto-microbiome. Its second product, Synergro Free and future generations of Inocucor products are powerful biological formulations for bio-stimulation, bio-fertility and bio-control targeting mainstream production agriculture.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.inocucor.com
  • 4600 South Ulster Street Suite 1325
    Denver, CO USA 80237
  • Phone: 720.543.0350

Executives

Name Title Contact Details

Similar Companies

Global BioChem

Global BioChem is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunocellular Therapeutics (Fka: Optical Molecular Imaging Inc)

Immunocellular Therapeutics Ltd (Fka: Optical Molecular Imaging Inc) is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Gennao Bio

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.

Korro Bio

Korro Bio is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and common diseases. The company`s proprietary and modular platform, OPERA™ (Oligonucleotide promoted editing of RNA), builds on a deep understanding of ADAR biology, and combines data-driven design, oligo discovery and chemistry with clinically validated delivery vehicles, to achieve highly selective RNA editing. This unique technology enables the development of RNA editing therapeutics that deliver the functional benefits of gene therapy with a reversible, transient, titratable and specific treatment regimen, offering the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is based in Cambridge, Mass.